Premium
HIGH CR RATES IN RELAPSED/REFRACTORY (R/R) AGGRESSIVE B‐NHL TREATED WITH THE CD19‐DIRECTED CAR T CELL PRODUCT JCAR017 (TRANSCEND NHL 001)
Author(s) -
Abramson J.,
Palomba M.L.,
Gordon L.,
Lunning M.,
Arnason J.,
Wang M.,
ForeroTorres A.,
Albertson T.,
Allen T.,
Sutherland C.,
Xie B.,
Garcia J.,
Siddiqi T.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_127
Subject(s) - medicine , fludarabine , cytokine release syndrome , cyclophosphamide , refractory (planetary science) , gastroenterology , chemotherapy , surgery , urology , immunotherapy , chimeric antigen receptor , cancer , physics , astrobiology